Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 28.446
Filtrar
1.
J Ethnopharmacol ; 336: 118759, 2025 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-39209003

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Hypercholesterolemia (HLC) was a key risk factor for cardiovascular disease (CVD) characterized by elevated cholesterol levels, particularly LDL. While traditional Chinese medicine preparations Compound Danshen Pills(CDP) has been clinically used for hypercholesterolemia and coronary heart disease, its specific therapeutic effect on HLC remains understudied, necessitating further investigation into its mechanisms. AIM OF THE STUDY: The aim of this study was to explore the potential of CDP in treating HLC and elucidate its underlying mechanisms and active components. MATERIALS AND METHODS: A hypercholesterolemic lipemia rat model induced by a high-fat diet was employed. Network pharmacology combined with UHPLC-Q exactive orbitrap HRMS technique was used to predict the active components, targets and mechanisms of CDP for HLC. Histological analysis and serum biochemical assays were used to assess the therapeutic effect of CDP and its main active ingredient Sa B on hypercholesterolemic lipemia rat model. Immunofluorescence assays and western blotting were used to verify the mechanism of CDP and Sa B in the treatment of HLC. Metabolomics approach was used to demonstrate that CDP and Sa B affected the metabolic profile of HLC. RESULTS: Our findings demonstrated that both CDP and its main active ingredient Sa B significantly ameliorated hypercholesterolemic lipemic lesions, reducing levels of TC, LDL, AST, ALT, and ALP. Histological analysis revealed a decrease in lipid droplet accumulation and collagen fiber deposition in the liver, as well as reduced collagen fiber deposition in the aorta. Network pharmacology predicted potential targets such as PPARα and CYP27A1. Immunofluorescence assays and western blotting confirmed that CDP and Sa B upregulated the expression of Adipor1, PPARα and CYP27A1. Metabolomics analyses further indicated improvements in ABC transporters metabolic pathways, with differential metabolites such as riboflavin, taurine, and choline showed regression in levels after CDP treatment and riboflavin, L-Threonine, Thiamine, L-Leucine, and Adenosine showed improved expression after Sa B treatment. CONCLUSION: CDP and Sa B have been shown to alleviate high-fat diet-induced hypercholesterolemia by activating the PPAR pathway and improving hepatic lipid metabolism. Our study demonstrated, for the first time, the complex mechanism of CDP, Sa B in the treatment of hypercholesterolemia at the protein and metabolic levels and provided a new reference that could elucidate the pharmacological effects of traditional Chinese medicine on hypercholesterolemia from multiple perspectives.


Assuntos
Dieta Hiperlipídica , Medicamentos de Ervas Chinesas , Hipercolesterolemia , Metabolômica , Farmacologia em Rede , Ratos Sprague-Dawley , Salvia miltiorrhiza , Animais , Hipercolesterolemia/tratamento farmacológico , Medicamentos de Ervas Chinesas/farmacologia , Medicamentos de Ervas Chinesas/uso terapêutico , Masculino , Cromatografia Líquida de Alta Pressão , Salvia miltiorrhiza/química , Ratos , Modelos Animais de Doenças , Fígado/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Canfanos , Panax notoginseng
2.
Nutrients ; 16(17)2024 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-39275232

RESUMO

Probiotics have shown potential in managing hypercholesterolemia and related metabolic conditions. This study evaluated the effects of Lactocaseibacillus (Lactobacillus) paracasei sup. paracasei TISTR 2593 on the gut microbiome and metabolic health in patients with hypercholesterolemia, and was registered in the Thai Clinical Trial Registry (TCTR 20220917002). In a randomized, double-blind, placebo-controlled trial, 22 hypercholesterolemic participants received either the probiotic or a placebo daily for 90 days. Fecal samples collected before and after the intervention revealed significant microbiome changes, including a decrease in Subdoligranulum, linked to rheumatoid arthritis, and an increase in Flavonifractor, known for its anti-inflammatory properties. Additionally, the probiotic group exhibited a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels. These findings suggest that L. paracasei TISTR 2593 can modulate the gut microbiome and improve metabolic health, warranting further investigation into its mechanisms and long-term benefits.


Assuntos
LDL-Colesterol , Fezes , Microbioma Gastrointestinal , Hipercolesterolemia , Probióticos , Humanos , Probióticos/administração & dosagem , Probióticos/uso terapêutico , Microbioma Gastrointestinal/efeitos dos fármacos , Hipercolesterolemia/terapia , Hipercolesterolemia/sangue , Masculino , Feminino , Método Duplo-Cego , Pessoa de Meia-Idade , Fezes/microbiologia , LDL-Colesterol/sangue , Lacticaseibacillus paracasei , Adulto , Suplementos Nutricionais , Idoso
3.
Int J Mol Sci ; 25(17)2024 Sep 02.
Artigo em Inglês | MEDLINE | ID: mdl-39273484

RESUMO

Hypercholesterolemia forms the background of several cardiovascular pathologies. LDL receptor-knockout (LDLR-KO) mice kept on a high-fat diet (HFD) develop high cholesterol levels and atherosclerosis (AS). Cannabinoid type 1 receptors (CB1Rs) induce vasodilation, although their role in cardiovascular pathologies is still controversial. We aimed to reveal the effects of CB1Rs on vascular function and remodeling in hypercholesterolemic AS-prone LDLR-KO mice. Experiments were performed on a newly established LDLR and CB1R double-knockout (KO) mouse model, in which KO and wild-type (WT) mice were kept on an HFD or a control diet (CD) for 5 months. The vascular functions of abdominal aorta rings were tested with wire myography. The vasorelaxation effects of acetylcholine (Ach, 1 nM-1 µM) were obtained after phenylephrine precontraction, which was repeated with inhibitors of nitric oxide synthase (NOS) and cyclooxygenase (COX), Nω-nitro-L-arginine (LNA), and indomethacin (INDO), respectively. Blood pressure was measured with the tail-cuff method. Immunostaining of endothelial NOS (eNOS) was carried out. An HFD significantly elevated the cholesterol levels in the LDLR-KO mice more than in the corresponding WT mice (mean values: 1039 ± 162 mg/dL vs. 91 ± 18 mg/dL), and they were not influenced by the presence of the CB1R gene. However, with the defect of the CB1R gene, damage to the Ach relaxation ability was moderated. The blood pressure was higher in the LDLR-KO mice compared to their WT counterparts (systolic/diastolic values: 110/84 ± 5.8/6.8 vs. 102/80 ± 3.3/2.5 mmHg), which was significantly elevated with an HFD (118/96 ± 1.9/2 vs. 100/77 ± 3.4/3.1 mmHg, p < 0.05) but attenuated in the CB1R-KO HFD mice. The expression of eNOS was depressed in the HFD WT mice compared to those on the CD, but it was augmented if CB1R was knocked out. This newly established double-knockout mouse model provides a tool for studying the involvement of CB1Rs in the development of hypercholesterolemia and atherosclerosis. Our results indicate that knocking out the CB1R gene significantly attenuates vascular damage in hypercholesterolemic mice.


Assuntos
Modelos Animais de Doenças , Hipercolesterolemia , Camundongos Knockout , Receptor CB1 de Canabinoide , Receptores de LDL , Vasodilatação , Animais , Hipercolesterolemia/metabolismo , Hipercolesterolemia/genética , Hipercolesterolemia/patologia , Camundongos , Receptor CB1 de Canabinoide/metabolismo , Receptor CB1 de Canabinoide/genética , Receptores de LDL/genética , Receptores de LDL/metabolismo , Receptores de LDL/deficiência , Vasodilatação/efeitos dos fármacos , Dieta Hiperlipídica/efeitos adversos , Masculino , Óxido Nítrico Sintase Tipo III/metabolismo , Aterosclerose/metabolismo , Aterosclerose/genética , Aterosclerose/patologia , Aterosclerose/etiologia , Remodelação Vascular/efeitos dos fármacos , Camundongos Endogâmicos C57BL , Acetilcolina/farmacologia
4.
Korean J Intern Med ; 39(5): 717-730, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39252486

RESUMO

Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes of hypercholesterolemia and hypertriglyceridemia include an unhealthy diet, diseases and metabolic conditions affecting lipid levels, and therapeutic side effects. It is imperative to correct secondary causes prior to initiating conventional lipid-lowering therapy. Guideline-based lipid therapy can then be administered based on the subsequent lipid levels.


Assuntos
Consenso , Dislipidemias , Hipolipemiantes , Humanos , Hipolipemiantes/uso terapêutico , Dislipidemias/sangue , Dislipidemias/diagnóstico , Dislipidemias/tratamento farmacológico , Dislipidemias/terapia , Biomarcadores/sangue , Hipertrigliceridemia/diagnóstico , Hipertrigliceridemia/sangue , Hipertrigliceridemia/terapia , Fatores de Risco , Hipercolesterolemia/sangue , Hipercolesterolemia/complicações , Hipercolesterolemia/diagnóstico , Hipercolesterolemia/tratamento farmacológico , Resultado do Tratamento , Triglicerídeos/sangue
5.
Lipids Health Dis ; 23(1): 290, 2024 Sep 10.
Artigo em Inglês | MEDLINE | ID: mdl-39256734

RESUMO

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients with atherosclerotic cardiovascular disease (CVD) or those at very high risk do not reach their therapeutic LDLc objectives. OBJECTIVE: The analysis aimed to examine the clinical and biochemical characteristics of subjects receiving PCSK9i treatment in the Dyslipidemia Registry of the Spanish Atherosclerosis Society. METHODS: All consecutive subjects aged ≥ 18 years from different Lipid Units included in the Dyslipidemia Registry of the SEA were analyzed. Inclusion criteria consisted of unrelated patients aged ≥ 18 at the time of inclusion with hypercholesterolemia (LDL-C ≥ 130 mg/dL or non-HDL-C ≥ 160 mg/dL after the exclusion of secondary causes) who were studied for at least two years after inclusion. Participants' baseline and final visit clinical and biochemical characteristics were analyzed based on whether they were on primary or secondary prevention and whether they were taking PCSK9i at the end of follow-up. RESULTS: Eight hundred twenty-nine patients were analyzed, 7014 patients in primary prevention and 1281 in secondary prevention at baseline. 4127 subjects completed the required follow-up for the final analysis. The median follow-up duration was 7 years (IQR 3.0-10.0). Five hundred patients (12.1%) were taking PCSK9i at the end of the follow-up. The percentage of PCSK9i use reached 35.6% (n = 201) and 8.7% (n = 318) in subjects with and without CVD, respectively. Subjects on PCSK9i and oral lipid-lowering agents with and without CVD achieved LDLc reductions of 80.3% and 75.1%, respectively, concerning concentrations without lipid-lowering drugs. Factors associated with PCSK9i use included increasing age, LDLc without lipid-lowering drugs and the Dutch Lipid Clinic Network (DLCN) score. However, hypertension, diabetes, smoking, and LDLc after oral lipid-lowering drugs were not independent factors associated with PCSK9i prescription. In subjects with CVD, the use of PCSK9i was higher in men than in women (an odds ratio of 1.613, P = 0.048). CONCLUSIONS: Approximately one-third of CVD patients received PCSK9i at the end of follow-up. The use of PCSK9i was more focused on baseline LDLc concentrations rather than on CVD risk. Women received less PCSK9i in secondary prevention compared to men.


Assuntos
Doenças Cardiovasculares , LDL-Colesterol , Inibidores de PCSK9 , Prevenção Secundária , Humanos , Inibidores de PCSK9/uso terapêutico , Masculino , Feminino , Pessoa de Meia-Idade , Prevenção Secundária/métodos , Idoso , Doenças Cardiovasculares/prevenção & controle , Doenças Cardiovasculares/tratamento farmacológico , LDL-Colesterol/sangue , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/sangue , Prevenção Primária/métodos , Anticolesterolemiantes/uso terapêutico , Sistema de Registros , Pró-Proteína Convertase 9/metabolismo , Anticorpos Monoclonais Humanizados/uso terapêutico
6.
JCI Insight ; 9(17)2024 Sep 10.
Artigo em Inglês | MEDLINE | ID: mdl-39253968

RESUMO

Emerging studies suggest that various parental exposures affect offspring cardiovascular health, yet the specific mechanisms, particularly the influence of paternal cardiovascular disease (CVD) risk factors on offspring cardiovascular health, remain elusive. The present study explores how paternal hypercholesterolemia affects offspring atherosclerosis development using the LDL receptor-deficient (LDLR-/-) mouse model. We found that paternal high-cholesterol diet feeding led to significantly increased atherosclerosis in F1 female, but not male, LDLR-/- offspring. Transcriptomic analysis highlighted that paternal hypercholesterolemia stimulated proatherogenic genes, including Ccn1 and Ccn2, in the intima of female offspring. Sperm small noncoding RNAs (sncRNAs), particularly transfer RNA-derived (tRNA-derived) small RNAs (tsRNAs) and rRNA-derived small RNAs (rsRNAs), contribute to the intergenerational transmission of paternally acquired metabolic phenotypes. Using a newly developed PANDORA-Seq method, we identified that high-cholesterol feeding elicited changes in sperm tsRNA/rsRNA profiles that were undetectable by traditional RNA-Seq, and these altered sperm sncRNAs were potentially key factors mediating paternal hypercholesterolemia-elicited atherogenesis in offspring. Interestingly, high-cholesterol feeding altered sncRNA biogenesis-related gene expression in the epididymis but not testis of LDLR-/- sires; this may have led to the modified sperm sncRNA landscape. Our results underscore the sex-specific intergenerational effect of paternal hypercholesterolemia on offspring cardiovascular health and contribute to the understanding of chronic disease etiology originating from parental exposures.


Assuntos
Aterosclerose , Hipercolesterolemia , Receptores de LDL , Animais , Aterosclerose/genética , Aterosclerose/etiologia , Masculino , Hipercolesterolemia/genética , Feminino , Camundongos , Receptores de LDL/genética , Camundongos Knockout , Modelos Animais de Doenças , Pequeno RNA não Traduzido/genética , Espermatozoides/metabolismo , Fatores Sexuais , Exposição Paterna/efeitos adversos
7.
Medicine (Baltimore) ; 103(36): e39308, 2024 Sep 06.
Artigo em Inglês | MEDLINE | ID: mdl-39252316

RESUMO

Proprotein Convertase Subtilisin/Kexin type-9 (PCSK-9) inhibitors have recently used in the management of different cardiac complications. Several clinical trials demonstrated their effectiveness in patients with hypercholesterolemia. However, the effectiveness of these medications in patients with heart diseases is still controversial. To review and summarize the clinical trials pertaining to the use and effectiveness of PCSK-9 inhibitors in heart diseases and to discuss the pharmacotherapy of these agents. A review was conducted of all clinical trials with PCSK-9 inhibitors for heart diseases registered at ClinicalTrials.gov since inception up to and including January 19th, 2024. These trials were retrieved. Data from these trials were extracted manually, categorized and analyzed. The number of identified clinical trials was 25,371. After screening and excluding irrelevant studies, 12 studies met the search criteria. The majority of these studies were conducted in the US. The total number of patients in these studies was 27,700. Alirocumab and Evolocumab were the most frequently used PCSK-9 inhibitors. This review identified only a few clinical trials on PCSK-9 inhibitors in heart disease patients. Therefore, it is recommended to conduct more randomized controlled clinical trials on PCSK-9 inhibitors in this patient population.


Assuntos
Anticorpos Monoclonais Humanizados , Cardiopatias , Inibidores de PCSK9 , Humanos , Anticorpos Monoclonais Humanizados/uso terapêutico , Cardiopatias/tratamento farmacológico , Anticolesterolemiantes/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Pró-Proteína Convertase 9
8.
G Ital Cardiol (Rome) ; 25(9): 650-659, 2024 Sep.
Artigo em Italiano | MEDLINE | ID: mdl-39239816

RESUMO

Due to the growing evidence of clinical benefits conferred by the reduction of low-density lipoprotein cholesterol (LDL-C) levels, the availability of multiple effective lipid-lowering agents, and guideline recommendations, clinicians not infrequently have to manage patients with low or very low LDL-C levels. In clinical practice it is essential to consider that, when LDL-C plasma concentrations are low, the Friedewald formula commonly used for LDL-C level calculation is less accurate, hence risk assessment should be integrated by using different methods for LDL-C level quantification and other parameters, such as non-high-density lipoprotein cholesterol and, where possible, apolipoprotein B, should be measured. As regards the clinical impact of low LDL-C levels, genetically determined hypocholesterolemia forms provide reassuring data on the effects of this condition in the long term, except for the forms with extremely low or undetectable LDL-C levels. Evidence from clinical studies that used highly effective lipid-lowering drugs, such as proprotein convertase subtilisin/kexin type 9 inhibitors, goes in the same direction. In these studies, the incidence of non-cardiovascular adverse events in patients who reached very low LDL-C levels was similar to that in the placebo arm. Overall, the fear of adverse effects should not deter intensive lipid-lowering treatment when indicated to reduce the risk of cardiovascular events.


Assuntos
Anticolesterolemiantes , LDL-Colesterol , Hipercolesterolemia , Humanos , LDL-Colesterol/sangue , Anticolesterolemiantes/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/sangue , Medição de Risco , Doenças Cardiovasculares/prevenção & controle , Doenças Cardiovasculares/etiologia , Inibidores de PCSK9
9.
Nutrients ; 16(15)2024 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-39125351

RESUMO

Syrian hamsters are valuable models for studying lipid metabolism due to their sensitivity to dietary cholesterol, yet the precise impact of varying cholesterol levels has not been comprehensively assessed. This study examined the impact of varying dietary cholesterol levels on lipid metabolism in Syrian hamsters. Diets ranging from 0% to 1% cholesterol were administered to assess lipid profiles and oxidative stress markers. Key findings indicate specific cholesterol thresholds for inducing distinct lipid profiles: below 0.13% for normal lipids, 0.97% for elevated LDL-C, 0.43% for increased VLDL-C, and above 0.85% for heightened hepatic lipid accumulation. A cholesterol supplementation of 0.43% induced hypercholesterolemia without adverse liver effects or abnormal lipoprotein expression. Furthermore, cholesterol supplementation significantly increased liver weight, plasma total cholesterol, LDL-C, and VLDL-C levels while reducing the HDL-C/LDL-C ratio. Fecal cholesterol excretion increased, with stable bile acid levels. High cholesterol diets correlated with elevated plasma ALT activities, reduced hepatic lipid peroxidation, and altered leptin and CETP levels. These findings underscore Syrian hamsters as robust models for hyperlipidemia research, offering insights into experimental methodologies. The identified cholesterol thresholds facilitate precise lipid profile manipulation, enhancing the hamster's utility in lipid metabolism studies and potentially informing clinical approaches to managing lipid disorders.


Assuntos
Colesterol na Dieta , Metabolismo dos Lipídeos , Fígado , Mesocricetus , Animais , Colesterol na Dieta/administração & dosagem , Fígado/metabolismo , Masculino , Cricetinae , Fezes/química , Estresse Oxidativo , Hipercolesterolemia/metabolismo , Hipercolesterolemia/sangue , LDL-Colesterol/sangue , Peroxidação de Lipídeos , Colesterol/sangue , Colesterol/metabolismo , Ácidos e Sais Biliares/metabolismo , Leptina/sangue , Leptina/metabolismo , Proteínas de Transferência de Ésteres de Colesterol/metabolismo
10.
Lipids Health Dis ; 23(1): 250, 2024 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-39154177

RESUMO

INTRODUCTION: Hypercholesterolemia is associated with increased inflammation and impaired serotonin neurotransmission, potentially contributing to depressive symptoms. However, the role of statins, particularly pitavastatin, in modulating serotonin transporter (SERT) function within this context remains underexplored. This study aimed to investigate whether pitavastatin counteracts the neurobiological effects of hypercholesterolemia. METHODS: Low-density lipoprotein receptor knockout (LDLR-/-) mice on a C57BL/6 background were assigned to three groups: a control group fed a standard chow diet, a group fed a high-fat diet (HFD), and a third group fed a high-fat diet supplemented with pitavastatin (HFD + Pita). We evaluated the effects of HFD with or without pitavastatin on lipid profiles, inflammatory markers, and SERT availability using small-animal positron emission tomography (PET) scans with the radioligand 4-[18F]-ADAM over a 20-week period. RESULTS: Pitavastatin treatment in HFD-fed mice significantly reduced both total cholesterol and LDL cholesterol levels in HFD-fed mice compared to those on HFD alone. Elevated inflammatory markers such as IL-1α, MCP-1/CCL2, and TNF-α in HFD mice were notably decreased in the HFD + Pita group. PET scans showed reduced SERT availability in the brains of HFD mice; however, pitavastatin improved this in brain regions associated with mood regulation, suggesting enhanced serotonin neurotransmission. Additionally, the sucrose preference test showed a trend towards increased preference in the HFD + Pita group compared to the HFD group, indicating a potential reduction in depressive-like behavior. CONCLUSION: Our findings demonstrate that pitavastatin not only lowers cholesterol and reduces inflammation but also enhances SERT availability, suggesting a potential role in alleviating depressive symptoms associated with hypercholesterolemia. These results highlight the multifaceted benefits of pitavastatin, extending beyond its lipid-lowering effects to potentially improving mood regulation and neurotransmitter function.


Assuntos
Dieta Hiperlipídica , Hipercolesterolemia , Camundongos Endogâmicos C57BL , Quinolinas , Proteínas da Membrana Plasmática de Transporte de Serotonina , Animais , Quinolinas/farmacologia , Quinolinas/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/metabolismo , Proteínas da Membrana Plasmática de Transporte de Serotonina/metabolismo , Proteínas da Membrana Plasmática de Transporte de Serotonina/genética , Camundongos , Dieta Hiperlipídica/efeitos adversos , Masculino , Camundongos Knockout , Receptores de LDL/metabolismo , Receptores de LDL/genética , Tomografia por Emissão de Pósitrons , LDL-Colesterol/sangue , Encéfalo/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/diagnóstico por imagem , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
11.
Hum Genomics ; 18(1): 85, 2024 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-39090729

RESUMO

Sitosterolemia is a rare inherited disorder caused by mutations in the ABCG5/ABCG8 genes. These genes encode proteins involved in the transport of plant sterols. Mutations in these genes lead to decreased excretion of phytosterols, which can accumulate in the body and lead to a variety of health problems, including premature coronary artery disease. We conducted the first genome-wide association study (GWAS) in the Middle East/North Africa population to identify genetic determinants of plant sterol levels in Qatari people. GWAS was performed on serum levels of ß-sitosterol and campesterol using the Metabolon platform from Qatar Biobank (QBB) and genome sequence data provided by Qatar Genome Program. A trans-ancestry meta-analysis of data from our Qatari cohort with summary statistics from a previously published large cohort (9758 subjects) of European ancestry was conducted. Using conditional analysis, we identified two independent single nucleotide polymorphisms associated with ß-sitosterol (rs145164937 and rs4299376), and two others with campesterol (rs7598542 and rs75901165) in the Qatari population in addition to previously reported variants. All of them map to the ABCG5/8 locus except rs75901165 which is located within the Intraflagellar Transport 43 (IFT43) gene. The meta-analysis replicated most of the reported variants, and our study provided significant support for the association of variants in SCARB1 and ABO with sitosterolemia. Evaluation of a polygenic risk score devised from European GWAS data showed moderate performance when applied to QBB (adjusted-R2 = 0.082). These findings provide new insights into the genetic architecture of phytosterol metabolism while showing the importance including under-represented populations in future GWAS studies.


Assuntos
Membro 5 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Membro 8 da Subfamília G de Transportadores de Cassetes de Ligação de ATP , Estudo de Associação Genômica Ampla , Erros Inatos do Metabolismo Lipídico , Fitosteróis , Polimorfismo de Nucleotídeo Único , Sitosteroides , Humanos , Fitosteróis/sangue , Fitosteróis/genética , Fitosteróis/efeitos adversos , Polimorfismo de Nucleotídeo Único/genética , Sitosteroides/sangue , Erros Inatos do Metabolismo Lipídico/genética , Erros Inatos do Metabolismo Lipídico/sangue , Membro 5 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/genética , Membro 8 da Subfamília G de Transportadores de Cassetes de Ligação de ATP/genética , Masculino , Feminino , Enteropatias/genética , Enteropatias/sangue , Adulto , Colesterol/sangue , Colesterol/análogos & derivados , Hipercolesterolemia/genética , Hipercolesterolemia/sangue , Pessoa de Meia-Idade , Lipoproteínas/sangue , Lipoproteínas/genética , Transportadores de Cassetes de Ligação de ATP/genética
13.
Nutrients ; 16(16)2024 Aug 22.
Artigo em Inglês | MEDLINE | ID: mdl-39203947

RESUMO

Hypercholesterolemia plays a pivotal role in the development and progression of cardiovascular diseases, and its prevention seems to be a crucial healthcare strategy to ameliorate these conditions. Subjects with mild hypercholesterolemia are frequently advised against using cholesterol-lowering drugs due to potential side effects, with an emphasis instead on prioritizing dietary adjustments and lifestyle modifications as the primary strategy. In this context, the use of dietary supplements based on medicinal plants may be recommended as a complementary approach to managing elevated cholesterol levels. The aim of this study was to investigate the safety and potential therapeutic effectiveness of a standardized formulation containing extracts from garlic and onions in addressing the health concerns of individuals with slightly elevated cholesterol levels. A controlled, randomized, double-blind, two parallel-group study was conducted over 8 weeks, with clinical visits scheduled at baseline, weeks 2 and 4, as well as at the end of the study. The results revealed significant reductions in both low-density lipoprotein cholesterol and total cholesterol levels among participants who received the extract. Additionally, improvements in blood pressure, as well as in oxidative and inflammatory markers were observed, thus suggesting its potential as a valuable therapeutic intervention for managing mild hypercholesterolemia.


Assuntos
LDL-Colesterol , Suplementos Nutricionais , Alho , Hipercolesterolemia , Cebolas , Extratos Vegetais , Humanos , Alho/química , Extratos Vegetais/farmacologia , Masculino , Método Duplo-Cego , Feminino , Adulto , Hipercolesterolemia/tratamento farmacológico , Hipercolesterolemia/sangue , LDL-Colesterol/sangue , Pessoa de Meia-Idade , Cebolas/química , Voluntários Saudáveis , Anticolesterolemiantes , Pressão Sanguínea/efeitos dos fármacos , Biomarcadores/sangue
14.
Bull Exp Biol Med ; 177(3): 395-400, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-39134815

RESUMO

We compared 2 models of metabolic syndrome in rats: high-fat diet (58% calories) with single streptozotocin injection at a dose of 25 mg/kg and replacement of water with 20% fructose solution. The model with fructose solution did not cause the main signs of metabolic syndrome over 24 weeks: concentrations of glucose, triglycerides, cholesterol, weight, and BP did not significantly differ from the control group (standard diet). At the same time, single streptozotocin administration was followed by the development of persistent hyperglycemia, hypertriglyceridemia, hypercholesterolemia, and signs of visceral obesity. High-fat diet combined with injection of streptozotocin in a low dose can be considered a more representative model of metabolic syndrome in humans.


Assuntos
Glicemia , Dieta Hiperlipídica , Síndrome Metabólica , Estreptozocina , Triglicerídeos , Animais , Dieta Hiperlipídica/efeitos adversos , Ratos , Masculino , Síndrome Metabólica/metabolismo , Triglicerídeos/sangue , Triglicerídeos/metabolismo , Glicemia/metabolismo , Ratos Wistar , Hiperglicemia/metabolismo , Hiperglicemia/induzido quimicamente , Colesterol/sangue , Colesterol/metabolismo , Peso Corporal/efeitos dos fármacos , Frutose/administração & dosagem , Hipertrigliceridemia/metabolismo , Hipertrigliceridemia/induzido quimicamente , Hipertrigliceridemia/sangue , Hipertrigliceridemia/etiologia , Hipercolesterolemia/metabolismo , Hipercolesterolemia/etiologia , Carboidratos da Dieta/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos
15.
Arterioscler Thromb Vasc Biol ; 44(9): 2069-2087, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39087348

RESUMO

BACKGROUND: Dyslipidemia increases cardiovascular disease risk, the leading cause of death worldwide. Under time-restricted feeding (TRF), wherein food intake is restricted to a consistent window of <12 hours, weight gain, glucose intolerance, inflammation, dyslipidemia, and hypercholesterolemia are all reduced in mice fed an obesogenic diet. LDLR (low-density lipoprotein receptor) mutations are a major cause of familial hypercholesterolemia and early-onset cardiovascular disease. METHODS: We subjected benchmark preclinical models, mice lacking LDLR-knockout or ApoE knockout to ad libitum feeding of an isocaloric atherogenic diet either ad libitum or 9 hours TRF for up to 13 weeks and assessed disease development, mechanism, and global changes in hepatic gene expression and plasma lipids. In a regression model, a subset of LDLR-knockout mice were ad libitum fed and then subject to TRF. RESULTS: TRF could significantly attenuate weight gain, hypercholesterolemia, and atherosclerosis in mice lacking the LDLR-knockout mice under experimental conditions of both prevention and regression. In LDLR-knockout mice, increased hepatic expression of genes mediating ß-oxidation during fasting is associated with reduced VLDL (very-low-density lipoprotein) secretion and lipid accumulation. Additionally, increased sterol catabolism coupled with fecal loss of cholesterol and bile acids contributes to the atheroprotective effect of TRF. Finally, TRF alone or combined with a cholesterol-free diet can reduce atherosclerosis in LDLR-knockout mice. However, mice lacking ApoE, which is an important protein for hepatic lipoprotein reuptake do not respond to TRF. CONCLUSIONS: In a preclinical animal model, TRF is effective in both the prevention and regression of atherosclerosis in LDLR knockout mice. The results suggest TRF alone or in combination with a low-cholesterol diet can be a lifestyle intervention for reducing cardiovascular disease risk in humans.


Assuntos
Aterosclerose , Modelos Animais de Doenças , Fígado , Camundongos Knockout para ApoE , Receptores de LDL , Animais , Receptores de LDL/genética , Receptores de LDL/deficiência , Aterosclerose/prevenção & controle , Aterosclerose/genética , Aterosclerose/metabolismo , Aterosclerose/etiologia , Fígado/metabolismo , Masculino , Camundongos Endogâmicos C57BL , Fatores de Tempo , Jejum/sangue , Camundongos , Hipercolesterolemia/genética , Hipercolesterolemia/metabolismo , Hipercolesterolemia/complicações , Dieta Aterogênica , Aumento de Peso , Camundongos Knockout , Doenças da Aorta/prevenção & controle , Doenças da Aorta/genética , Doenças da Aorta/patologia , Doenças da Aorta/metabolismo , Lipídeos/sangue , Apolipoproteínas E
16.
Pharmacol Res ; 207: 107340, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39111557

RESUMO

Randomized clinical trials (RCTs) of PCSK9 monoclonal antibody(mAb) specifically for Chinese patients have been limited. This multi-center RCT is to clarify the efficacy and safety of a novel mAb, Ebronucimab, in Chinese patients. Patients diagnosed with primary hypercholesterolemia, including Heterozygous Familial Hypercholesterolemia, or mixed dyslipidemia, were categorized by ASCVD risk and randomly assigned at a ratio of 2:1:2:1 to receive Ebronucimab 450 mg or matching placebo every 4 weeks (Q4W), or Ebronucimab 150 mg or matching placebo every 2 weeks (Q2W). The primary outcome was the percentage change of LDL-C from baseline to week 12 for all groups. The least squares mean reduction difference (95 %CI) in LDL-C from baseline to week 12 of Ebronucimab 450 mg Q4W and Ebronucimab 150 mg Q2W groups versus the placebo group was -59.13 (-64.103, -54.153) (Adjusted p<0.0001) and -60.43 (-65.450, -55.416) (Adjusted p<0.0001), respectively. Meanwhile, the Ebronucimab group exhibited notably high rates in reaching LDL-C goals of each cardiovascular risk stratification. In addition, Ebronucimab effectively improved other lipid panel. During the double-blind treatment period, relatively frequently reported adverse events (AEs) were injection site reactions (ISR), urinary tract infection, and hyperuricemia (Incidence rate are 6.9 %, 4.8 % and 3.5 %). Among treatment-associated AEs, only injection site reactions (ISR) occurred more in the dose groups. In conclusion, Ebronucimab, with either 450 mg Q4W or 150 mg Q2W doses, demonstrated significant efficacy in lowering serum LDL-C level with a favorable safety and immunogenicity profile among hypercholesterolemic patients.


Assuntos
Anticorpos Monoclonais Humanizados , LDL-Colesterol , Hipercolesterolemia , Humanos , Masculino , Pessoa de Meia-Idade , Método Duplo-Cego , Feminino , Hipercolesterolemia/tratamento farmacológico , Anticorpos Monoclonais Humanizados/efeitos adversos , Anticorpos Monoclonais Humanizados/uso terapêutico , LDL-Colesterol/sangue , Adulto , Resultado do Tratamento , Povo Asiático , Idoso , Anticolesterolemiantes/uso terapêutico , Anticolesterolemiantes/efeitos adversos , China , População do Leste Asiático , Pró-Proteína Convertase 9
17.
Biomed Pharmacother ; 178: 117244, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-39116783

RESUMO

Atherosclerosis, the leading cause of cardiovascular disease, cannot be sufficiently explained by established risk factors, including cholesterol. Elevated plasma homocysteine (Hcy) is an independent risk factor for atherosclerosis and is closely linked to cardiovascular mortality. However, its role in atherosclerosis has not been fully clarified yet. We have previously shown that rabbits fed a diet deficient in B vitamins and choline (VCDD), which are required for Hcy degradation, exhibit an accumulation of macrophages and lipids in the aorta, aortic stiffening and disorganization of aortic collagen in the absence of hypercholesterolemia, and an aggravation of atherosclerosis in its presence. In the current study, plasma Hcy levels were increased by intravenous injections of Hcy into balloon-injured rabbits fed VCDD (VCDD+Hcy) in the absence of hypercholesterolemia. While this treatment did not lead to thickening of aortic wall, intravenous injections of Hcy into rabbits fed VCDD led to massive accumulation of VLDL-triglycerides as well as significant impairment of vascular reactivity of the aorta compared to VCDD alone. In the aorta intravenous Hcy injections into VCDD-fed rabbits led to fragmentation of aortic elastin, accumulation of elastin-specific electron-dense inclusions, collagen disorganization, lipid degradation, and autophagolysosome formation. Furthermore, rabbits from the VCDD+Hcy group exhibited a massive decrease of total protein methylated arginine in blood cells and decreased creatine in blood cells, serum and liver compared to rabbits from the VCDD group. Altogether, we conclude that Hcy contributes to atherogenic transformation of the aorta not only in the presence but also in the absence of hypercholesterolemia.


Assuntos
Aorta , Aterosclerose , Homocisteína , Hipercolesterolemia , Animais , Coelhos , Aterosclerose/patologia , Aterosclerose/metabolismo , Homocisteína/sangue , Aorta/patologia , Aorta/metabolismo , Hipercolesterolemia/sangue , Hipercolesterolemia/metabolismo , Hipercolesterolemia/patologia , Masculino , Colina/administração & dosagem , Modelos Animais de Doenças , Elastina/metabolismo , Complexo Vitamínico B/administração & dosagem , Complexo Vitamínico B/farmacologia
18.
Front Cell Infect Microbiol ; 14: 1408581, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39119290

RESUMO

Background: Statins, being the primary pharmacological intervention for hypercholesterolemia, exhibit a notable degree of interpatient variability in their effectiveness, which may be associated with gut microbiota. This study sought to identify the biomarkers for evaluating differences in statin efficacy. Methods: A quasi case-control study was conducted among participants with hypercholesterolemia and coronary heart disease taking rosuvastatin essential. According to the level of low density lipoprotein cholesterol (LDL-C), participants was divided into the "Up to standard" (US) group and the "Below standard" (BS) group. 16S rDNA sequencing and untargeted metabolomics were applied to detected the information of gut microbiota and related metabolites. Results: A total of 8 US and 8 BS group matched by age and sex were included in the final analysis. 16S rDNA sequencing results indicated that the characteristic strains of the US group were f-Eubacterium_coprostanoligenes and g-Papillibacter, while the characteristic flora of the BS group were o-C0119, g-Pseudolabrys, s-Dyella-Marensis and f-Xanthobacaceae. Metabolomic results suggested that the levels of chenodeoxycholic acid-3-ß-D-glucuronide, 1-methylnicotinamide and acetoacetate in stool samples of the US group were significantly higher than those of the BS group. By identifying the differentially abundant bacterial taxa, the gut microbiota could modulate the efficacy of statins through producing enzymes involved in cholesterol metabolism. Conclusions: The findings suggest that the difference in statin efficacy may be related to gut microbiota strains that can produce short-chain fatty acids and secondary bile acids and affect the efficacy of statins by regulating the activities of cholesterol metabolite-related proteins. Metabolites related to short-chain fatty acids and secondary bile acids in the gut are expected to be biomarkers indicating the efficacy of statins.


Assuntos
Doença das Coronárias , Microbioma Gastrointestinal , Inibidores de Hidroximetilglutaril-CoA Redutases , Hipercolesterolemia , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Bactérias/metabolismo , Ácidos e Sais Biliares/metabolismo , Biomarcadores/sangue , Estudos de Casos e Controles , China , LDL-Colesterol/sangue , LDL-Colesterol/metabolismo , Doença das Coronárias/microbiologia , Doença das Coronárias/tratamento farmacológico , Doença das Coronárias/metabolismo , População do Leste Asiático , Fezes/microbiologia , Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico , Hipercolesterolemia/tratamento farmacológico , Metabolômica , RNA Ribossômico 16S/genética , Rosuvastatina Cálcica/uso terapêutico , Resultado do Tratamento
19.
Int J Circumpolar Health ; 83(1): 2386783, 2024 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-39106414

RESUMO

The anthropometric index that best predicts cardiometabolic risk remains inconclusive. This study therefore assessed the prevalence of obesity using six indices and compared their associations with obesity-related cardiometabolic disorders. We determined obesity prevalence according to body mass index, waist circumference, waist-to-hip ratio, waist-to-height ratio (WHtR), body fat percentage and fat mass index (FMI) using data from the Know Your Heart study (n = 4495, 35-69 years). The areas under the receiver operating characteristic curves (AUCs) provided predictive values of each index for detecting the presence of hypertension, hypercholesterolaemia and diabetes. Age-standardised obesity prevalence significantly varied according to anthropometric index: from 17.2% (FMI) to 75.8% (WHtR) among men and from 23.6% (FMI) to 65.0% (WHtR) among women. WHtR had the strongest association with hypertension (AUC = 0.784; p < 0.001) and with a combination of disorders (AUC = 0.779; p < 0.001) in women. In women, WHtR also had the largest AUCs for hypercholesterolaemia, in men - for hypertension, diabetes and a combination of disorders, although not all the differences from other obesity indices were significant. WHtR exhibited the closest association between hypertension and a combination of disorders in women and was non-inferior compared to other indices in men.


Assuntos
Diabetes Mellitus , Hipercolesterolemia , Hipertensão , Obesidade , Humanos , Masculino , Pessoa de Meia-Idade , Obesidade/epidemiologia , Feminino , Hipertensão/epidemiologia , Adulto , Prevalência , Hipercolesterolemia/epidemiologia , Federação Russa/epidemiologia , Idoso , Diabetes Mellitus/epidemiologia , Índice de Massa Corporal , Antropometria , Fatores de Risco
20.
PeerJ ; 12: e17169, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-39026536

RESUMO

Background: Hypercholesterolemia is the most common form of dyslipidaemia in the world leading to negative health effects, both physical and mental. Physical activity (PA) can reduce total cholesterol and has positive effects on mental health. This retrospective cross-sectional study analyses the relationships between physical activity level (PAL), self-perceived health (SPH) and mental health. Methods: This study was based on data from the Spanish National Health Survey 2017 (SNHS 2017), with 3,176 Spanish adults with high cholesterol as participants. Non-parametric tests were used as the data did not follow normality. Results: Dependent relationships were found between PAL and SPH, depression and anxiety. Women had higher depression and anxiety prevalences than men, while men were more likely to report being very active, although the proportion of walkers was higher in women. The physically inactive population presented higher negative SPH, depression and anxiety proportions and psychological distress than physically active people. Conclusion: The physically inactive people had a higher risk of negative SPH, depression and anxiety. Regular PA may improve SPH and mental health in people with high cholesterol, but more studies are needed to establish causal relationships, mechanisms, and optimal doses.


Assuntos
Ansiedade , Depressão , Exercício Físico , Hipercolesterolemia , Humanos , Feminino , Masculino , Estudos Transversais , Estudos Retrospectivos , Exercício Físico/psicologia , Espanha/epidemiologia , Pessoa de Meia-Idade , Depressão/epidemiologia , Depressão/psicologia , Adulto , Ansiedade/epidemiologia , Ansiedade/psicologia , Hipercolesterolemia/epidemiologia , Hipercolesterolemia/psicologia , Idoso , Inquéritos Epidemiológicos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA